News Release

Bio Bridge I Fund Managed by Our Investment Subsidiary Invests in NATiAS Inc.

Tokyo, Japan – July 31, 2026 – Nano Holdings, Inc. hereby announces that Bio Bridge I, a fund managed by its investment subsidiary Nano Bridge Investment Co., Ltd. ("NBI"), has made an investment in NATiAS Inc.

NBI determined that NATiAS possesses strong global competitive advantages through its proprietary Blockmer® technology, as well as a proven track record of being selected for major national projects. These strengths align closely with the NANO Group's Gateway Model, which aims to enhance corporate value by connecting outstanding Japanese technologies with global capital and international networks. Based on this assessment, NBI decided to make the investment.

Overview of NATiAS Inc.
Headquarters: 5-5-2 Minatojima-Minamimachi, Chuo-ku, Kobe, Japan
Representative: Masanori Kataoka, Representative Director
Established: October 2, 2015
Business: Manufacture and sale of nucleic acid pharmaceutical ingredients based on long-chain nucleic acid synthesis technologies

NATiAS is a deep-tech company developing nucleic acid materials and manufacturing technologies for nucleic acid therapeutics, mRNA therapeutics, and genome editing applications. Leveraging its proprietary Blockmer® technology, the company is advancing manufacturing efficiency, reducing impurities, and enabling large-scale production of long-chain nucleic acids that have been difficult to manufacture using conventional methods.

Proprietary Technology — Blockmer®
Blockmer® is a proprietary nucleic acid synthesis technology that assembles nucleic acids in block units. The technology is protected by patents in Japan, the United States, Europe, China, and India.
Conventional nucleic acid synthesis requires bases to be added one at a time, causing the number of manufacturing steps to increase as the target nucleic acid becomes longer. This leads to greater impurity generation, increasingly complex purification processes, material loss, higher manufacturing costs, and increased waste. These challenges are particularly significant for long-chain nucleic acids such as guide RNA for genome editing.
Compared with conventional methods, Blockmer® significantly shortens manufacturing processes while enabling the production of high-quality long-chain nucleic acids, making it an important platform technology for next-generation modalities including genome editing and mRNA therapeutics.

Diversified Business Portfolio and Growth Potential
NATiAS has established a balanced business portfolio ranging from proprietary products to CDMO services and technology licensing.

1. Manufacturing, Sales, and Licensing of Blockmer® Technology and Nucleic Acid Materials
The company supplies products to research institutions and pharmaceutical companies worldwide. Through its licensing agreement with a leading U.S. chemical manufacturer, NATiAS is promoting the commercialization of Blockmer® in North American and European markets.
2. CDMO Services for Nucleic Acids and mRNA-Related Materials
NATiAS provides contract manufacturing services for long-chain nucleic acids, including guide RNA for genome editing, as well as difficult-to-synthesize modified nucleic acids. The company also supplies CAP analogs used in mRNA manufacturing.

Recognition by Government and Public Institutions
NATiAS' technologies have been recognized as important for strengthening Japan's pharmaceutical and vaccine manufacturing infrastructure and have been selected for several national programs, including:

- Ministry of Economy, Trade and Industry (METI) — Bio-manufacturing Infrastructure Development Program (Dual-Use Subsidy): Development of domestic production capacity for essential vaccine materials such as CAP analogs and nucleic acid adjuvants, supporting both routine pharmaceutical demand and emergency supply to vaccine manufacturers in the event of a pandemic or other crises.
- Japan Agency for Medical Research and Development (AMED) — CiCLE Program: Demonstrated 1 kg-scale production and purification of nucleic acid APIs using the Blockmer® liquid-phase segment synthesis method, validating its scalability for high-purity, large-scale manufacturing.
- Small and Medium Enterprise Agency (SMEA) — Go-Tech Program: Development of continuous nucleic acid manufacturing equipment in collaboration with universities to improve productivity through automation and continuous processing.
- METI Kansai Bureau — J-Startup KANSAI: Selected as a promising startup recognized for its novelty and originality, competitive advantage, growth potential, and international outlook, expected to expand from the Kansai region to all of Japan and the world.

To provide our stakeholders with a deeper understanding of the background of this investment, as well as NATiAS' proprietary Blockmer® technology and business operations, the Company plans to release an introductory video in the near future.
As this investment was made through the Bio Bridge I fund, the investment amount has not been disclosed.

Investor and Media Contact
Nano Holdings, Inc.
Corporate Communication
https://www.nano-hd.com/en